Why the MAVERIC Trial Design is "Smart" / Higher Probability of Success ($CRDL)

I dug into the clinical trial design for Cardiol Therapeutics' ($CRDL) pivotal Phase 3 MAVERIC trial, and I wanted to share why this specific setup is interesting from a risk/reward perspective. 

Phase 3 studies often face variability in placebo responses, and Cardiol has thoughtfully designed the MAVERIC trial to overcome that challenge of uncertainty. 

• The Indication: Recurrent Pericarditis (RP). 
• The Patients: They are recruiting patients who have been on IL-1 blockers for 12+ months and are scheduled to stop. 
• The Risk: These patients have a notoriously high recurrence rate (up to 75%) when they stop treatment. 

By targeting this specific "high-risk-to recur" group, the placebo arm of the trial will have known high rate of recurrence (flares). This makes for an efficient design  to demonstrate a potential statistically significant benefit of CardiolRx vs placebo by recruiting  smaller sample sizes. 

They are targeting 100% patient enrollment in Q2 2026 and have already achieved >50%. If the drug works as well as it did in Phase 2 (where it showed rapid, durable symptom relief and a meaningful reduction in annual recurrences), this trial design maximizes the chance of a clear "win."